Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile

June 2010
Journal of Nutrition, Health & Aging;Jun2010, Vol. 14 Issue 6, p457
Academic Journal
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial. Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC. Subjects ≥55 years old with high cardiovascular disease risk profile. The intervention consisted of 6-month administration of fosinopril vs. placebo. Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired t-tests. The mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported. A six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance.


Related Articles

  • Renal growth hormone -- Insulin-like growth factor-I system in acute renal failure. Tsao, Tanny; Jin Wang; Fervenza, Fernando C.; Vu, Thanh H.; Jin, Isabelle H.; Hoffman, Andrew R.; Rabkin, Ralph // Kidney International;Jun1995, Vol. 47 Issue 6, p1658 

    The renal growth hormone—insulin-like growth factor-I system in acute ischemic renal failure. Recovery from acute tubular necrosis (ATN) is accelerated by IGF-I therapy. Furthermore, the local renal growth hormone-IGF-I system may participate in the natural repair. We examined the IGF-I...

  • Insulin-Like Growth Factor I: Implications in Aging. Arvat, E.; Broglio, F.; Ghigo, E. // Drugs & Aging;2000, Vol. 16 Issue 1, p29 

    According to the somatomedin model, growth hormone (GH)-dependent hepatic synthesis is responsible for maintaining circulating insulin-like growth factor (IGF)-I levels. On the other hand, the local autocrine/paracrine IGF-I expression in peripheral tissue is generally GH-independent and...

  • Insulin-Like Growth Factors Expression.  // Current Medical Literature: GH & Growth Factors;2003, Vol. 18 Issue 1, p24 

    Presents citations and clinicians' notes on insulin-like growth factors (IGF) expression. Effect of glucocorticoid treatment on IGF-I and its binding proteins in children with nephrotic syndrome; Association of low serum IGF-I with increased risk of ischemic heart disease; Dietary correlates of...

  • Failure of IGF-A and IGFBP-3 to diagnose growth-hormone insufficiency.  // European Journal of Pediatrics;2000, Vol. 159 Issue 1/2, pA128 

    Presents information on a study that tested the reliability of insulin-like growth factor I (IGF-1) testing alone and in combination with the determination of IGF binding protein (IGFBP). Measurement of the concentrations of IGF-1 and IGFBP-3 in serum samples; Assessment of various cut-off...

  • Targeting the IGF-1 Pathways. Schor, Jacob // Townsend Letter;Aug/Sep2015, Issue 385/386, p56 

    The article explains the functions of the insulin-like growth factors (IGF)-1 to optimize the dietary and lifestyle strategies in treating cancer. Topics discussed include IGF-1 and IGF2 as proteins produced by the liver in response to growth hormone from the pituitary gland in the brain, the...

  • Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associaated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes. Heald, Adrian H.; Siddals, K.W.; Fraser, William; Taylor, William; Kaushal, Kalpana; Morris, Julie; Young, Robert J.; White, Anne; Gibson, J. Martin // Diabetes;Aug2002, Vol. 51 Issue 8, p2629 

    The IGF system is increasingly implicated in the development of cardiovascular disease. The effects of circulating IGFs on the vasculature are largely modulated by IGFBPs, which control their access to cell-surface IGF receptors. IGFBP-1 has been proposed as the acute regulator of IGF...

  • Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein Therapy for Diabetes. Clemmons, David R. // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2006, Vol. 1 Issue 4, p91 

    The article reviews several studies which utilized insulin-like growth factor-1(IGF-1) and insulin growth factor-binding proteins (IGFBP) for the treatment of diabetes. Adverse events associated with IGF-1 therapy is discussed. Study findings suggest that the administration of IGF-1 and IGFBP-3...

  • IGF.  // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2009, Vol. 2 Issue 3, p82 

    The article cites two researches on insulin-like growth factors (IGF). The first study links IGF and their binding proteins to subsequent risk of prostate cancer, while the other shows evidence for relationships between IGF and neoplasia. Data collected from the first study showed that the risk...

  • Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Wilczak, N.; Ramsaransing, G. S. M.; Mostert, J.; Chesik, D.; de Keyser, J. // Multiple Sclerosis (13524585);Feb2005, Vol. 11 Issue 1, p13 

    Using radioimmunoassay we measured serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 in patients with relapsing multiple sclerosis (MS) and a benign course (Expanded Disability Status Scale (EDSS) = 3 despite > 10 years disease duration), relapsing MS with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics